Conclusions: Vitamin D supplementation was associated with reduced intestinal inflammation in patients with active UC, with a concomitant increase in Enterobacteriaceae but no change in overall faecal microbial diversity.
Introduction
With expanding therapeutic options for inflammatory bowel diseases [IBD] , the costs associated with medical therapies have risen disproportionately to those associated with disease complications. 1 Numerous epidemiological and laboratory-based immunological studies support the role of vitamin D as a potential inexpensive immunomodulator, and serum 25 [OH] vitamin D (25[OH]D) status has been shown to be inversely proportional to intestinal inflammation in patients with IBD. [2] [3] [4] [5] [6] [7] [8] However, there remains a paucity of interventional data supporting vitamin D as a treatment for patients with IBD.
Dysbiosis, or dysregulation of the gut microbiota, is a recognized feature of IBD, and is thought to play a role in the pathogenesis and perpetuation of inflammation. 9 Patients with ulcerative colitis [UC] have reduced bacterial species richness, as well as temporal instability of the microbiota profile in clinical remission and in active disease, compared with healthy controls. [10] [11] [12] Members of the phyla Firmicutes and Bacteroidetes have been demonstrated to be reduced in patients with IBD. 10 Increases in pathobiont bacterial species including Fusobacterium nucleatum and Escherichia coli have been shown in the mucosa and faeces of patients with UC, 13, 14 whilst the immunoregulatory species Faecalibacterium prausnitzii has been shown to be under-represented. 15 Mucolytic bacterial species including Ruminococcus gnavus and Ruminococcus torques are also disproportionately increased in abundance in patients with IBD, with the suggestion that increased numbers contributes towards the gut environment changes seen as the disease progresses. 16 Therapeutically targeting the microbiota using the broad approach of faecal microbiota transfusion has been shown to improve outcomes in patients with UC. [17] [18] [19] There is evidence that vitamin D may modify the gut microbiota. Specifically, vitamin D supplementation has been shown to suppress intra-macrophage Escherichia coli survival in in vitro studies. 20 Vitamin D has also been shown to regulate anti-microbial peptide production. [20] [21] [22] Vitamin D-deficient and vitamin D receptor [VDR] knockout mice have reduced ileal Paneth cell alpha defensin secretion, increased abundance of Helicobacter hepaticus and reduced abundance of Akkermansia muciniphila, compared with control or wild-type mice. 23 Studies have also shown that VDR negatively regulates bacterial-induced intestinal epithelial NFκB activation and response to infection. 24 Conversely, a cross-sectional study of 150 young healthy adults found an inverse correlation between 25 [OH]D status and faecal abundance of butyrate producing bacterium Coprococcus, as well as Bifidobacterium, both of which may theoretically mediate an anti-inflammatory effect. 25 It is currently unknown whether vitamin D supplementation in patients with UC affects pro-inflammatory or anti-inflammatory gut microbiota as part of a strategy to influence disease activity.
This prospective pilot study aimed to evaluate changes in subjective and objective markers of intestinal inflammation, and within the faecal microbiota, following vitamin D replacement in patients with active and inactive UC, and in non-IBD controls. 
Materials and Methods

Subjects and study protocol
PCR amplification and sequencing
The V3-4 region of the 16S rRNA gene was amplified using primers Bakt_341F and Bakt_805R, as described previously, 31 
Bioinformatic analysis
Sequence quality was assessed using FastQC [version 0.11.3]. 32 The V3-V4 primer sequences at the 5′ end of reads were hard trimmed using TrimGalore! [version 0.4.0]. 33 Sequences were analysed using DADA2 [version 1.3.1] to produce sequence variants. Taxonomy was assigned against the GreenGenes 13.8 database. 34 The outcome sequence variant table was converted to biom format using biomformat [version 2.1.3]. 35 Further details regarding bioinformatic analysis are presented in Supplementary Material 1.
Diversity analyses including Simpson Index for alpha diversity and Bray-Curtis statistic for beta diversity were performed using the core_diversity_analyses.py script from QIIME [version 1. 
Ethical statement
The protocol for this study was approved by the Office of Research and Ethics at London Northwest Healthcare NHS Trust, and was performed in accordance with UK regulations and the principles of the Declaration of Helsinki 1954 and its later amendments. Informed consent was obtained from all individual participants included in this study.
Results
Twenty-five patients participated in this study from August to December 2015 [late Summer to Winter at 52°N], with baseline characteristics outlined in Table 1 . No significant demographic differences were noted across the three groups. A trend to higher body mass index [BMI] and waist circumference in non-IBD controls was seen. Most patients with UC had left-sided or extensive colitis of variable duration.
Routine laboratory indices and circulating components of the vitamin D axis amongst participants at baseline are outlined in Table 2 . As expected, faecal calprotectin was significantly higher amongst patients with active disease, and platelet counts higher, with a trend towards higher C-reactive protein [CRP] . No significant differences across the groups in serum 25 
Change in faecal microbiota
All 25 patients submitted a faecal sample at baseline, with 23 patients also providing a follow-up sample. One patient with active colitis and one non-IBD control did not submit follow-up samples for microbiota analysis.
Between 
Diversity analyses
No differences in alpha diversity as assessed by the Simpson, Shannon, Chao or Observed species diversity indices were noted across the three patient groups at baseline. No differences in alpha diversity were noted in samples following vitamin D replacement across the patient groups.
PCoA plots using the Bray-Curtis beta diversity metric demonstrated that patients without IBD clustered together distinct from UC patients [ Figure 2a ; p = 0.003, PERMANOVA]. When the same analysis approach was applied to both the data for before and after vitamin D supplementation, no difference between patients with inactive and active UC was noted [p = 1.0, Figure 2b ].
Taxonomic profiling
Changes in the relative abundance of sequence variants showed statistically significant differences between the three groups at baseline [ Table 3 ]. Abundance of the mucus-associated bacterium Ruminococcus gnavus was marginally but not significantly higher in patients with UC than non-IBD controls [p = 0.068, Kruskal-Wallis test, Supplementary Figure 1] .
Changes in the abundance of specific bacteria following vitamin D administration were analysed using LEfSe analysis. Across all participants, an increase in Clostridium colinae [p = 0.03; driven by two non-IBD controls and two patients with inactive UC] and Enterobacteriacae [p = 0.03; driven by five patients with inactive UC and three with active UC] was noted. Ruminococcus gnavus decreased marginally but not significantly following vitamin D supplementation across the whole cohort [p = 0.15; Wilcoxon Rank sum, Supplementary DM, diabetes mellitus; BMI, body mass index; SCCAI, Simple Clinical Colitis Activity Index; Fitzpatrick skin types: I -pale white skin, blue/hazel eyes, blond/ red hair, II -fair skin, blue eyes, III -darker white skin, IV -light brown skin, V -brown skin, VI -dark brown or black skin. 
Discussion
The role of vitamin D as a potential immunomodulator in patients with IBD has been investigated extensively for over a decade.
Numerous studies demonstrate involvement of the vitamin D axis in regulation of the epithelial barrier, and innate immune cell and T-cell function. 20, 21, 23, 24, [40] [41] [42] [43] [44] [45] [46] [47] Although there are some preliminary data suggesting that vitamin D may influence the intestinal microbiota in IBD, this has not been studied in humans. Furthermore, evidence for efficacy at the clinical level remains poor. This study is the first to show that vitamin D replacement in patients with active UC who are deficient in vitamin D improved objective markers of inflammation. Although this was associated with a significant increase in Enterobacteriacae in patients with UC, there was no change in overall diversity or other specific bacteria analysed. Previous studies have shown that vitamin D supplementation may be associated with reduced rates of relapse in patients with Crohn's disease in remission when given at a dose of 1200 IU daily for 12 months, 2 and improved Crohn's disease activity index [CDAI] and quality of life when given at up to 5000 IU daily for 24 weeks. 4 An alternative placebo-controlled randomized controlled trial showed no significant change in CDAI, quality of life, CRP or faecal calprotectin in patients given 2000 IU vitamin D daily for 3 months. 5 In patients with UC, low vitamin D levels have been associated with greater disease activity, as assessed by symptoms, faecal calprotectin and endoscopic activity, as well as increased risk of subsequent relapse. 7, 8, [48] [49] [50] A small pilot study demonstrated reduction in symptomatic disease activity indices but not intestinal inflammation as measured by faecal calprotectin in patients with UC and Crohn's colitis. 51 No placebo-controlled studies in patients with UC have been reported to date. The current study is the first to show an improvement in objective markers of inflammation [faecal calprotectin, albumin, platelet count] following vitamin D replacement, limited to a group of patients with active UC defined by faecal calprotectin ≥ 100 µg/g at baseline.
The reason for the faecal calprotectin reduction in these patients warrants further consideration. Although it has been postulated that a 25 [OH]D level higher than 75 nmol/l, or closer to 100-125 nmol/l, may be required for an immunomodulatory effect, The VDR is expressed in colonic intestinal epithelial cells, dendritic cells and macrophages. 21, 42 Vitamin D has been shown to potently stimulate cathelicidin, an anti-microbial peptide produced by macrophages 22 which plays an important role in defence against intracellular organisms such as mycobacteria. 21 VDR expression is significantly increased in inflamed and non-inflamed mucosal biopsies from patients with UC. 55 Vitamin D supplementation suppressed intra-macrophage E. coli survival in in vitro studies, 20 and vitamin D-deficient and VDR knockout mice had impaired ileal Paneth cell alpha defensin secretion and increased abundance of the colitogenic Helicobacter hepaticus, compared with control or wild-type mice. 23 Therefore, there is biological plausibility for an interaction between the vitamin D axis and intestinal microbiota in the pathogenesis and perpetuation of inflammation in patients with IBD, especially UC. In the current study, no overall change in faecal microbial diversity occurred following vitamin D supplementation. Although an increase in the abundance of Enterobacteriaecae was noted following vitamin D supplementation in patients with UC, this large family comprises a large proportion of harmless and commensal as well as potentially pathogenic bacteria in the human gut, and therefore the significance of such a change is uncertain.
Ruminococcus gnavus is a Gram-positive anaerobic mucolytic bacterium belonging to Cluster XIVa of the class Clostridia, which is increased in abundance in patients with IBD. 16 The intestinal mucus layer provides a protective barrier between the luminal environment and mucosa, comprising dense glycoproteins interspersed with antimicrobial peptides produced by Paneth cells and other epithelial cells. 56 A previous study has shown reduced abundance of Ruminococcus gnavus in mucosal biopsies from patients with active UC defined symptomatically, 57 and this trend was confirmed in the current study, albeit without statistical significance. Furthermore, the abundance of Ruminococcus gnavus decreased non-significantly across all patients after vitamin D supplementation. Whether vitamin D supplementation mediates regulation of intestinal mucus antimicrobial composition and therefore susceptibility to specific mucolytic bacteria warrants further investigation.
Nonetheless, an absence of a significant effect on the faecal microbiota across the whole cohort of patients studied is of note. It is possible that vitamin D does not alter human microbiota, despite laboratory data from mouse studies. 23 Other possible explanations include a differential effect on faecal and mucosa-associated microbiota. Faecal microbiota was assessed during this study rather than mucosal-associated microbiota as this is less invasive and is not subject to variation as a result of bowel preparation. 58 However, given the intimate relationship between vitamin D-induced anti-microbial peptide secretion and the mucosal microbiota, one may postulate that significant changes in the latter may be more reflective of the effect of vitamin D in this setting. An absence of significant alteration of the faecal microbiota by vitamin D supplementation, however, is not an isolated finding: despite widespread use, there remains a paucity of published data regarding the effect of conventional therapies such as 5-aminosalicylates, thiopurines and anti-tumour necrosis factor α agents on the faecal microbiota independent of changes in mucosal inflammation in patients with IBD. 59, 60 Conversely, the absence of a change in microbiota composition despite reduction in inflammation in the active UC group is also notable, and may reflect only a mild reduction in inflammation in these patients. It is important to note that there are few robust data regarding change in microbiota composition in patients with UC in the absence of medical therapy. 61 Furthermore, patients with UC in this study had a relatively long disease duration, with a median of 11-12 years. Data regarding the effect of duration of UC on temporal variability of microbiota are also limited. 61 Longer disease duration has previously been described as a risk factor for vitamin D deficiency, 62 but no influence of disease activity on initial 25 [OH]D level or response to supplementation was noted in the current study [data not shown].
There are multiple other limitations in this small study. Although no overt toxicity as measured by serum calcium and phosphate was noted, long-term potential effects of the supplementation strategy in this study were not able to be elucidated, particularly the risk of hypercalciuria or nephrocalcinosis. 51 Dietary assessment of patients at baseline and follow-up visits showed no clear changes across most patients, but specific effects of change in diet as confounders were difficult to elicit.
In conclusion, vitamin D supplementation at a dose of 40 000 IU weekly for 8 weeks reduced objective circulating and intestinal markers of inflammation in patients with active UC. A significant increase in abundance of Enterobacteriaceae in patients with UC, and a trend to reduction in the mucolytic species Ruminococcus gnavus, was noted, but overall microbiota diversity was unchanged. Vitamin D may therefore reduce intestinal inflammation, but independently of any change in faecal bacterial composition. A larger placebo-controlled clinical trial incorporating immunological and extended microbiota analyses, including functional assessment, will shed further light upon this effect. 
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